Muhammad Furqan
Alliance for Clinical Trials in Oncology · Holden Comprehensive Cancer Center · University of Iowa
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Muhammad Furqan as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 15:24 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07388524 · Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC TrialNational Cancer Institute (NCI) · recruiting · Lung Non-Small Cell Carcinoma · principal investigator
- Ph2NCT06107374 · Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAGCellSight Technologies, Inc. · unknown · Advanced Non Small Cell Lung Cancer · principal investigator
- Ph2NCT06084806 · Test-retest Evaluation of [18F]F-AraG PETCellSight Technologies, Inc. · unknown · Non-small Cell Lung Cancer · principal investigator
- Ph2NCT04699838 · Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung CancerMuhammad Furqan · active not recruiting · Extensive Stage Small Cell Lung Cancer · principal investigator
- Ph1NCT03982134 · PDR001 + Panobinostat for Melanoma and NSCLCMuhammad Furqan · withdrawn · Melanoma, Non Small Cell Lung Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 15:24 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Clinical Protocol and Data ManagementP30CA086862 · NCI · UNIVERSITY OF IOWA · fiscal years 2024 to 2026 · $139,949 awarded in 2026Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Alliance for Clinical Trials in Oncology Member Site CoreU10CA180821 · NCI · ALLIANCE NCTN FOUNDATION · PI Evanthia Galanis · fiscal years 2014 to 2026Named on NCT07388524
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 15:24 UTC. The ranking covers the 200 most relevant of 13 PubMed records, and a shared surname and initials can bring in a namesake. All 13 on PubMed
- O2⋅- and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate.Cancer Cell · 2017324 citationsRCR 11.3
- Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial.Nat Med · 2024243 citationsRCR 26.9
- 74 citationsRCR 13.3
- Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial.Nat Med · 202466 citationsRCR 7.2
- Multisite, Randomized Trial of Early Integrated Palliative and Oncology Care in Patients with Advanced Lung and Gastrointestinal Cancer: Alliance A221303.J Palliat Med · 202051 citationsRCR 2.8
- A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients with Small Cell Lung Cancer.Clin Cancer Res · 202447 citationsRCR 4.3
- Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors.ESMO Open · 202246 citationsRCR 2.7
- Pharmacological ascorbate improves the response to platinum-based chemotherapy in advanced stage non-small cell lung cancer.Redox Biol · 202239 citationsRCR 2.9
- 28 citationsRCR 1.4
- 17 citationsRCR 1.4